![Christopher Turner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christopher Turner
Hoofd Techniek/Wetenschap/O&O bij
NUVALENT, INC.
Vermogen: 4 M $ op 30-06-2026
Profiel
Dr. Christopher D.
Turner, MD, is a Chief Medical Officer at Nuvalent, Inc. Dr. Turner was previously employed as a Vice President-Clinical Development by Blueprint Medicines Corp., a Vice President-Clinical Science by Celldex Therapeutics, Inc., a Head-Clinical Research by ARIAD Pharmaceuticals, Inc., a Director-Pediatric Neuro Oncology Outcomes by Dana-Farber Cancer Institute, Inc., and a Director-Pediatric Neuro Oncology Outcomes Clinic by The Children's Hospital Corp.
He received his undergraduate degree from Bowdoin College and a doctorate degree from the University of Rochester School of Medicine & Dentistry.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 31.530 ( 0,05% ) | 4 M $ | 30-06-2026 |
Actieve functies van Christopher Turner
| Bedrijven | Functie | Begin |
|---|---|---|
| NUVALENT, INC. | Hoofd Techniek/Wetenschap/O&O | 01-03-2021 |
Eerdere bekende functies van Christopher Turner
| Bedrijven | Functie | Einde |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Corporate Officer/Principal | 01-03-2021 |
| CELLDEX THERAPEUTICS, INC. | Corporate Officer/Principal | 01-05-2018 |
| ARIAD PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2014 |
The Children's Hospital Corp.
 The Children's Hospital Corp. Medical/Nursing ServicesHealth Services Provides pediatric care services | Corporate Officer/Principal | - |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Corporate Officer/Principal | - |
Opleiding van Christopher Turner
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
45
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
Bowdoin College
 Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Children's Hospital Corp.
The Children's Hospital Corp. Medical/Nursing ServicesHealth Services Provides pediatric care services | Health Services |
Celldex Therapeutics, Inc.
 Celldex Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes immunotherapy technologies for the treatment of cancer and other diseases | Health Technology |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
University of Rochester School of Medicine & Dentistry
 University of Rochester School of Medicine & Dentistry Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
Kies MarketScreener 
